English  |  正體中文  |  简体中文  |  Items with full text/Total items : 18055/20253 (89%)
Visitors : 5346      Online Users : 587
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: https://ir.cnu.edu.tw/handle/310902800/30959

    標題: Pegylated Liposomal Doxorubicin as Adjuvant Therapy for Stage I-III Operable Breast Cancer
    作者: Lu, Yin-Che
    Ou-Yang, Fu
    Hsieh, Chia-Ming
    Chang, King-Jen
    Chen, Dar-Ren
    Tu, Chi-Wen
    Wang, Hwei-Chung
    Hou, Ming-Feng
    貢獻者: Ditmanson Med Fdn Chiayi Christian Hosp, Dept 1Hematol Oncol
    Ditmanson Med Fdn Chiayi Christian Hosp, Dept Surg
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Kaohsiung Med Univ Hosp, Dept Surg
    Taiwan Adventist Hosp, Breast Ctr
    Natl Taiwan Univ Hosp, Dept Surg
    Cheng Ching Gen Hosp, Dept Surg
    Changhua Christian Hosp, Dept Surg
    China Med Univ Hosp, Dept Surg
    Kaohsiung Municipal Hsiaokang Hosp
    關鍵字: Breast cancer
    adjuvant chemotherapy
    pegylated liposomal doxorubicin
    日期: 2016-03
    上傳時間: 2018-01-18 11:38:44 (UTC+8)
    出版者: Int Inst Anticancer Research
    摘要: Background: Conventional anthracyclines play an essential role for the treatment of breast cancer and have potent cytotoxic activity, but are associated with severe toxicity. In metastatic breast cancer, pegylated liposomal doxorubicin (PLD) is a formulation with efficacy similar to conventional doxorubicin but with reduced toxicity. This multicenter study evaluated the efficacy and safety of PLD-based adjuvant chemotherapy for women with stage I-III operable breast cancer. Patients and Methods: One hundred and eighty women with stage I-III breast cancer who received PLD-based adjuvant chemotherapy at six different Institutions in Taiwan from February 2002 to March 2008 were included and followed-up until April 2015. Treatment efficacy was determined by disease-free survival (DFS) rate and safety was evaluated by adverse events. Results: The 5- and 10-year DFS rates were 76.3 and 72.6%, respectively. Univariate analysis revealed that tumor size >5 cm (p=0.045; hazard ratio=3.31) and stage III (hazard ratio=3.54; p=0.019) were each associated with shorter DFS. Only stage III (hazard ratio=5.60; p=0.018) retained statistical significance with regard to DFS in the multivariate analysis. Grade 3/4 hematological toxicity was neutropenia (n=13; 7.2%). The women receiving PLD had low-grade 3 or 4 nausea/vomiting, mucositis, and alopecia. Grade 3 hand-foot syndrome occurred in three patients (1.7%). Conclusion: PLD could be considered an effective and safe alternative to conventional anthracyclines in the treatment of stage I-III operable breast cancer.
    關聯: In Vivo, v.30 n.2, pp.158-162
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    30959.pdf77KbAdobe PDF439View/Open

    All items in CNU IR are protected by copyright, with all rights reserved.

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback